Objective This post hoc analysis of the SELECT-PsA 2 study evaluated long-term efficacy and safety of upadacitinib 15 mg once daily in patients with psoriatic arthritis (PsA) and exposure to one prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results